Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy

NCT02401542 is registered in ClinicalTrials.gov with Rainier Therapeutics as lead sponsor.

NCT NCT02401542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02401542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy
Lead sponsor
Rainier Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2015
Completion date
November 1, 2019
Enrollment
71 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urothelial cell carcinoma, urinary bladder disease, urological diseases